INMNasdaqPharmaceutical PreparationsFiscal year ends June 30

InMed Pharmaceuticals Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 9, 2026

$1.37+0.05 (+3.44%)

Close on Oct 19, 2026

Margins

Share of revenue, fiscal years 2019 to 2026

–

–

–

8 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2019	FY2021	FY2026
Return on equity	–	-154.0%	-173.1%
Return on assets	–	-116.1%	-135.0%
Current ratio	–	3.78	1.37
Inventory turnover	–	–	–
Capex to revenue	–	0.1%	–
Diluted shares	–	0M	4M

Return on equity split into margin, efficiency and leverage

Net margin-165.1%

Asset turnover0.36×

Equity multiplier1.21×

Return on equity, FY2025-72.1%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2025	-165.1%	0.36×	1.21×	-72.1%
FY2024	-166.9%	0.35×	1.22×	-72.1%
FY2023	-192.2%	0.31×	1.27×	-75.1%
FY2022	-1707.3%	0.10×	1.37×	-226.1%
FY2021	-535.9%	0.22×	1.33×	-154.0%